Solid Tumors Clinical Trials

548 recruitingLast updated: June 17, 2026

There are 548 actively recruiting solid tumors clinical trials across 57 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3, Phase 4. Top locations include Houston, Texas, United States, Nashville, Tennessee, United States, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Solid Tumors Trials at a Glance

548 actively recruiting trials for solid tumors are listed on ClinicalTrialsFinder across 6 cities in 57 countries. The largest study group is Phase 1 with 432 trials, with the heaviest enrollment activity in Houston, Nashville, and Beijing. Lead sponsors running solid tumors studies include Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd..

Browse solid tumors trials by phase

Treatments under study

About Solid Tumors Clinical Trials

Looking for clinical trials for Solid Tumors? There are currently 98 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Solid Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Solid Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 548 trials

Recruiting
Phase 1Phase 2

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced/Metastatic Solid Tumors
Crescent Biopharma, Inc.290 enrolled17 locationsNCT07335497
Recruiting

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Solid TumorOther Solid TumorsVery Rare Tumors+2 more
National Cancer Institute (NCI)4,000 enrolled1 locationNCT07489378
Recruiting
Phase 1

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Solid TumorPediatric Solid TumorMalignant Solid Tumors+2 more
National Cancer Institute (NCI)10,000 enrolled3 locationsNCT03739827
Recruiting
Phase 1Phase 2

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Refractory NeuroblastomaRefractory RhabdomyosarcomaRefractory Solid Tumors+3 more
Theodore Laetsch59 enrolled7 locationsNCT06721689
Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled8 locationsNCT07458347
Recruiting
Phase 1Phase 2

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

Advanced or Metastatic Solid Tumors
Takeda223 enrolled15 locationsNCT07205718
Recruiting
Phase 1

A Study of GEN1106 in Participants With Solid Tumors

Urothelial CarcinomaSolid Tumors
Genmab103 enrolled8 locationsNCT07416123
Recruiting
Phase 1

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Advanced Solid TumorsMetastatic Solid Tumors
Merck Sharp & Dohme LLC178 enrolled25 locationsNCT05853367
Recruiting
Phase 1

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer
Deborah Doroshow23 enrolled1 locationNCT04997993
Recruiting
Phase 1Phase 2

Study of CM518D1 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Keymed Biosciences Co.Ltd434 enrolled1 locationNCT07019779
Recruiting
Phase 1

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

KRAS Altered Advanced or Metastatic Solid Tumors
Amgen434 enrolled35 locationsNCT07094113
Recruiting
Phase 1

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

Metastatic Solid Tumors
Erasca, Inc.200 enrolled5 locationsNCT06983743
Recruiting
Phase 1

A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours.

Advanced Solid Tumors
Joint Biosciences Ltd.18 enrolled1 locationNCT07648472
Recruiting
Phase 1

A First-in-human Phase I Study to Evaluate EMB-15 in Patients With Locally Advanced or Metastatic Solid Tumors.

Locally Advanced or Metastatic Solid Tumors
Shanghai EpimAb Biotherapeutics Co., Ltd.50 enrolled1 locationNCT07607054
Recruiting
Phase 1

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.138 enrolled9 locationsNCT07360314
Recruiting
Phase 3

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled782 locationsNCT03486873
Recruiting
Phase 1Phase 2

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

Advanced Solid Tumors That Are MTAP Deficient
AstraZeneca334 enrolled21 locationsNCT06130553
Recruiting
Phase 1

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Colorectal, CancerMesothelin-Expressing TumorsEpithelial Ovarian Cancer+8 more
Context Therapeutics Inc.70 enrolled9 locationsNCT06756035
Recruiting
Phase 2

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Solid Tumors Harboring MET Amplification
AbbVie100 enrolled33 locationsNCT07196644